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An increasing number of patients older than 65 years
are referred for and have access to organ transplan-
tation, and an increasing number of older adults are
donating organs. Although short-term outcomes are
similar in older versus younger transplant recipients,
older donor or recipient age is associated with inferior
long-term outcomes. However, age is often a proxy for
other factors that might predict poor outcomes more
strongly and better identify patients at risk for ad-
verse events. Approaches to transplantation in older
adults vary across programs, but despite recent gains
in access and the increased use of marginal organs,
older patients remain less likely than other groups
to receive a transplant, and those who do are highly
selected. Moreover, few studies have addressed geri-
atric issues in transplant patient selection or manage-
ment, or the implications on health span and disability
when patients age to late life with a transplanted or-
gan. This paper summarizes a recent trans-disciplinary
workshop held by ASP, in collaboration with NHLBI,
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NIA, NIAID, NIDDK and AGS, to address issues related
to kidney, liver, lung, or heart transplantation in older
adults and to propose a research agenda in these areas.
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Introduction
The patient population on organ transplant waiting lists
is growing older, particularly as the number of patients
aged 65 years and older increases (1) (Figure 1). Older
adults have gained more access to transplantation over
time (2), but transplantation rates among these patients
still vary across organs (Figure 2). For kidney, the pro-
portion of older patients placed on the waiting list is
lower than that of other age groups, even though older
patients represent about half of all patients with end-
stage renal disease (ESRD). However, of the older pa-
tients listed for kidney transplant, the proportion who re-
ceive transplants is similar to that in younger age groups.
For lung, transplantation rates increase with age be-
cause of the high rate of transplantation for idiopathic
pulmonary fibrosis, a disorder primarily affecting older
adults (3).
The average age of donor organs is also increasing, but
the impact of older donor age on transplantation varies by
organ. On the basis of data from old studies, the clinical
decision to use ‘older’ hearts for transplantation is rare.
The number of heart donations remains flat overall, and
the number of older donors remains small. In contrast,
the number of lung and kidney donations is increasing (4),
even as the proportion of donors older than 65 years re-
mains flat. Lung transplant data suggest that donor organ
age has minimal impact on short-term survival and that a
combination of age and longer ischemic time (5), not donor
age alone, is associated with inferior outcomes. Similarly,
the outcomes for patients receiving older kidneys or livers
are only slightly worse than those for patients receiving
younger organs. Yet many transplantation centers still ex-
clude donors aged 55 years and older, and particularly for
kidney, organs from older donors are more likely to be dis-
carded (Figure 3) (1) when their inclusion could expand the
donor pool.
The likelihood of receiving organs from expanded criteria
donors (ECD) increases with recipient age (6,7). In addi-
tion, older donor age increases the likelihood that an or-
gan will be classified as ECD (8), but for heart and lung
donations, there are no common accepted definitions for
ECD organs. Thus classification of ECD organs often de-
pends on expert opinion and, in the case of the lung, on
criteria unrelated to risk factors that affect posttransplan-
tation outcomes. Moreover, despite evidence that some
patients will benefit from ECD organs (9), and even though
patients’ willingness to receive these organs can be influ-
enced by careful presentation of evidence (10), the pro-
portion of those patients who are willing to receive such
organs is low, even among centers with longer waiting
times (11).
Donor Organ Quality
Large studies, the majority of which have focused on kid-
ney transplantation, have shown that organ quality de-
clines with older donor age. The quantity and quality of
nephrons in the donor kidney, and particularly the initial
number of healthy glomeruli, are more important determi-
nants of allograft survival than donor age. Techniques to
accurately quantify the number of functioning glomeruli
have not yet been established, and surrogate measures,
such as body surface area (12) or kidney weight, are not
useful or practical in the existing allocation system (13). Es-
timates from autopsy studies in individuals without known
kidney disease suggest that on average, glomerular filtra-
tion rate and the number of functioning glomeruli decline
with age (14). Estimates based on renal physiology and
morphometry show similar numbers and trends for func-
tioning glomeruli in living donors (15) but a significantly
lower number in older deceased donors (16,17) (Figure
3). Consistent with these observations, allograft survival
is considerably better for living donor kidneys, even those
from older donors (18). However, the rate of allograft failure
is still excessive for older donor kidneys, compared with
younger ones.
Injury to renal tubular epithelial cells following procurement
and implantation (19,20) might also affect donor kidney
quality. The risk for ESRD following postischemic acute
renal failure is substantial among older adults, particularly
those with preexisting chronic kidney disease, compared
with younger patients (21). The mechanism of this injury
is unknown, but evidence suggests that repair of epithe-
lial cells is limited by cellular senescence, and atubular
glomeruli have been observed in kidneys from older adults
and in renal allografts with chronic allograft nephropathy
American Journal of Transplantation 2012; 12: 2608–2622 2609
Abecassis et al.
Figure 1: Proportion of pa-
tients on transplant waiting
lists, by age (1), for (A) kidney,
(B) liver, (C) lung and (D) heart.
(22). Thus in deceased donor allografts, the reduction of
the number of nephrons below a critical threshold could
render the allograft more susceptible to accelerated de-
cline, and subsequent injury from rejection or drug toxic-
ity could hasten complete allograft failure. Further study
on the mechanism and prevention of such injuries could
guide interventions to increase the longevity of allografts
from older donors.
Organ Allocation
Organ allocation systems vary by specific organ and by pro-
grammatic tendencies. The Lung Allocation Score, which
includes age as a variable, grades disease severity and
physiologic reserve. The Model for End-Stage Liver Dis-
ease (MELD) predicts waitlist mortality but predicts post-
transplant outcomes only at scores above 35. The likeli-
hood of patients dying while waiting for a liver depends
on the donor service area in which they reside. A regional
sharing and prioritization system for MELD scores of 15
or more has received widespread support, and recent ev-
idence (23) supports a similar system for MELD scores
higher than 35. An allocation system that accounts for sev-
eral predictors of posttransplant mortality and considers
posttransplant lifetime relative to lifetime on the waitlist
has also been proposed. However, this system is seen as
too complicated and thus has mixed support.
Kidney allocation policy is based primarily on waiting time
and local organ distribution, and it only minimally addresses
potential outcomes and immunologic matching. Thus the
potential survival of the donor organ and that of the recipi-
ent are often mismatched, increasing the need for retrans-
plant and decreasing the number of potential life-years real-
ized from a transplant. Moreover, current kidney allocation
does not consider recipient age, except for pediatric pa-
tients. Efforts to improve kidney allocation by age-matching
donors and recipients have been controversial because of
perceptions of age discrimination, and there is no evidence
that age matching improves outcomes (24). A newer model
incorporates longevity matching, which includes age and
other metrics for prediction, and replaces the current ECD
system with a Kidney Donor Profile Index score (25), which
accounts for several clinical and demographic factors, in-
cluding donor age. With this model, calculation of wait-
ing time includes the amount of time a patient has lived
with ESRD. Simulations suggest that the number of older
patients receiving kidneys will decrease by approximately
5%, based on a difference in average age between donors
2610 American Journal of Transplantation 2012; 12: 2608–2622
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Figure 2: Transplant rates for
adults on the waiting list, by
age (1), for (A) kidney, (B) liver,
(C) lung and (D) heart.
and recipients. However, allocation systems based more
heavily on recipient functional status and prognostic vari-
ables, rather than age alone, are more likely to be accept-
able to the public.
Recipient Selection and Management
Illness severity is often better than age in predicting post-
operative complications. However, despite recent gains in
access for older patients on the waiting list and evidence
that older patients benefit from transplantation if their wait-
ing time is shorter (26–29), older patients still have less
access to transplantation than other age groups because
they are not placed on the waiting list (30). Moreover, older
patients who are referred for transplant often are highly se-
lected, and they are less likely to receive an organ from a
living donor (31). Comprehensive risk assessments, based
on stronger predictors than age and accounting for end
points such as independence and quality of life, might be
needed to evaluate risk versus benefit for older recipients.
Transplant recipients are selected based on the likelihood
of successful outcomes, and age is often used as a
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Figure 3: Proportion of donor organs discarded, by age. (A)
Kidney, (B) liver. (Based on data from the United Network for
Organ Sharing (UNOS) Standard Transplant Analysis and Research
(STAR)).
determinant. However, age is a surrogate for many other
health and functional issues, and there is no specific pre-
dictive rule that examines most age-related variables to de-
termine which patients will do well after a transplant. Thus,
transplant physicians judge candidate suitability based on
their clinical experience and a subjective assessment of
physical fitness, or the so-called eyeball test. More ob-
jective measures of fitness have focused on lean trunk
muscle size for liver transplantation and a 6-minute walk
test for lung transplantation, and both of these factors cor-
relate with posttransplant survival (32,33). Among older
patients undergoing elective surgery, an American Soci-
ety of Anesthesiologists (ASA) risk score combined with
a frailty assessment is more predictive of outcomes than
the ASA score alone (34). In kidney transplant recipients,
frailty is strongly associated with early allograft dysfunc-
tion (35). Thus evaluations of physical performance, which
might better represent a patient’s physiologic age, might
prove a more objective approach to recipient selection.
While physical function can be affected by organ failure
and transplantation (36–39), it might also play a role in a re-
cipient’s posttransplantation recovery time, risk for disabil-
ity, cardiovascular health, and health-related quality of life
(HRQOL). Dialysis patients reporting a higher level of phys-
ical function are at lower risk for posttransplantation hos-
pitalizations and death (40), and posttransplantation gains
in exercise capacity and muscle strength are higher with
exercise than with usual care (41). To date, no exercise
intervention trials have examined the potential benefits
of pretransplant exercise on posttransplant outcomes in
ESRD patients.
For most solid organs, organ failure has been asso-
ciated with cognitive impairment (42–47), and several
potential mechanisms are supported by modest data
(42,48–54). Chronic organ failure has been associated with
encephalopathy and dementia, especially in renal disease,
and acute insult to the organ can cause delirium that, when
recurrent, can lead to chronic encephalopathy and demen-
tia. In addition, the risk for cognitive impairment increases
with age. Cognitive impairment leads to medical nonadher-
ence and thus to higher rejection rates (55–57). However,
the use of cognitive impairment as an exclusion criterion
for transplant varies by organ (58–61), and assessments
are usually done only if dementia is suspected, rather than
by formal, standard evaluation.
Psychosocial well-being improves after transplantation in
most patients, but not to normative levels. For example,
rates of emotional distress and psychiatric disorders are
higher, and the rate of gainful employment lower, among
transplant recipients, compared with the general popula-
tion (62–65). Psychosocial well-being is routinely assessed
to aid in decisions to list patients for transplants and to
guide interventions to ameliorate psychosocial contraindi-
cations to transplant (59,60,66). Posttransplant medical ad-
herence, mental health outcomes and quality of life for
older recipients are similar to, and occasionally better than,
those for younger recipients (67–71). Nevertheless, little
evidence suggests that age is a major predictor of post-
transplant psychosocial outcomes, and few analyses of
psychosocial well-being in transplant recipients have been
stratified by age. A more complete understanding of age
effects on psychosocial outcomes could aid the develop-
ment of interventions tailored to recipient age.
Comorbidities might also influence outcomes. For exam-
ple, postoperative survival is shorter among cancer pa-
tients who have two or more comorbidities when under-
going tumor resection (72). However, few data address the
impact of comorbidities on posttransplantation outcomes,
particularly in older patients. Thus preoperative assess-
ments of comorbidities vary across centers, and patients
older than 70 with multiple serious comorbidities are un-
likely to receive transplants unless their functional status
is exceptional. Risk assessments based on comorbidities
may be confounded by the primary organ failure that can
2612 American Journal of Transplantation 2012; 12: 2608–2622
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Figure 4: Changes in glo-
merular filtration rate
(GFR) and glomerluar
number, by age. (A)
Changes in GFR (17). (B)
Changes in glomerular
number, estimated from
autopsy studies (14). (C)
Changes in glomerular
number from deceased
donors, estimated by com-




studies (16). (D) Changes
in glomerular number from
living donors, estimated by
combining renal physiology
with morphometry from kid-
ney biopsies (15). Reprinted
with permission.
be reversed with transplantation, but few studies have ad-
dressed reversibility by age.
Immunosuppression in the Older Transplant
Recipient
Aging broadly influences diverse affects of immunity
including exaggerated inflammation and altered innate
immunity important in host defense (73,74), but cell-
mediated immunity is most clearly affected. A precipitous
decline in the production of naı̈ve T cells and a resulting
decline in T cell diversity have been observed in the older
immune system. In addition, clonally expanded T cells, par-
ticularly in the CD8 T cell compartment, lead to a narrower
repertoire and accumulation of ‘exhausted’ and ‘senes-
cent’ T cells (75–77). These changes can be exacerbated by
persistent viral infections such as cytomegalovirus, which
restimulates memory T cells over a lifetime (78–80). Senes-
cent T cells are marked by absent CD28 expression, in-
creased CD2 expression, altered dependence on costim-
ulation versus adhesion ligand-receptor interactions, and
overproduction of proinflammatory cytokines (81). As a re-
sult, mechanisms underlying organ rejection likely differ
between younger and older transplant recipients.
Consistent with this hypothesis, mouse studies suggest
that costimulation blockade is less effective in older indi-
viduals (82). Further, while immune senescence generally
impairs immune responses, the impact of acute rejection
is more profound in older recipients (83,84). In addition,
the risk for delayed graft function associated with acute
rejection (85–87) is higher for older donor organs. Thus,
the impact of the immunobiology of aging on transplanta-
tion deserves investigation, and immunosuppression pro-
tocols for older transplant recipients must balance the risk
for acute rejection with the risk for poor cardiovascular,
infectious and/or metabolic outcomes.
Immunosuppression protocols also must account for age-
related physiological changes that alter the pharmacokinet-
ics, pharmacodynamics, and potential toxicity of immuno-
suppressive drugs (88). Therapeutic blood target ranges
associated with efficacy and toxicity might be different in
older recipients. In addition, because older recipients are
more likely to have comorbidities and thus take multiple
medications, they are at higher risk for adverse drug in-
teractions. Studies exploring immunosuppressant pharma-
cokinetic disposition among older kidney recipients have
yielded mixed results (89–91), and their sample sizes are
too small for interpretation. Few studies have assessed an-
tibody therapy in the older recipient. Biologic assays that
measure overall immunosuppression would be useful.
Despite possible age-related immunologic and pharmaco-
logic changes, immunosuppression protocols are typically
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similar regardless of age (92). However, risk stratification
data suggest there is a link between IL-2RA and risk for
cardiovascular death and that the impact of acute rejec-
tion is most profound when both donor and recipient are
classified as high risk (92). Tailored immunosuppression
strategies such as calcineurin inhibitor avoidance (93,94)
and mycophenolic acid withdrawal (95) are designed to
reduce morbidity and might improve patient and graft sur-
vival. There are also likely to be important effects of age
on autonomic disturbances (e.g. postural hypotension) and
neuropsychiatric issues that could influence drug choices.
The benefit of steroid avoidance is less clear (96) but
perhaps more important in seniors in whom age-related
bone loss, glucose intolerance and other metabolic ef-
fects complicate steroid therapy. Moreover, previous stud-
ies are largely retrospective, single-center studies with-
out controls, and they have not collected data on older
patients.
Long-Term Outcomes
Although short-term outcomes are acceptable for older
transplant recipients across organs, long-term outcomes
differ by age (6,97). Older donor organs also have been
associated with inferior long-term outcomes (98), for ex-
ample increased risk for graft loss.
Older adults are more susceptible than young adults to in-
fections that are often more severe and arise from a wider
range of pathogens. Among waitlisted patients, the risk
for infection-related death increases with age (99). It is
not clear which changes in immunity contribute to these
risks, but immunosuppressive drugs further impair host
defenses. Risk for death from infection increases expo-
nentially with age among kidney transplant recipients (99),
and among kidney and lung recipients older than 60 years,
infection is the leading cause of increased mortality seen in
the first postoperative year (100,101). Yet no guidance ex-
ists to help clinicians prevent or manage infections in older
transplant patients. Multiple factors reduce host defense
in senior transplant recipients; vaccine efficacy decreases
markedly with age (102), antibiotic prophylaxis in older pa-
tients likely leads to complications such as C. difficile in-
fection or antimicrobial resistance in specific pathogens,
and less virulent pathogens (e.g. nonvaccine serotypes of
S. pneumoniae) cause disease more frequently in old than
young adults (103).
Cardiovascular disease (CVD) is an important predictor
of mortality in transplant recipients (104–106). Among
kidney recipients, even in those screened for CVD be-
fore transplantation, left ventricular dysfunction and a pa-
tient’s Framingham Risk Score can predict cardiac events
(105,106). In nontransplant patients, traditional risk fac-
tors such as hyperlipidemia or smoking can predict post-
operative cardiac risk, but coronary artery disease re-
vealed by coronary imaging further increases that risk,
even if the disease is not hemodynamically significant
(107). However, cardiac assessments of transplant can-
didates focus only on their ability to survive the surgery
itself. How best to predict long-term cardiac risk, par-
ticularly among patients with coronary disease, is not
clear.
Cancer incidence increases with age in the general popu-
lation. Overall, transplant recipients are at twice the age-
adjusted risk for cancers; the risk is elevated for non-
Hodgkin lymphoma and cancers of the lung and kidney,
but not for breast or prostate cancer (108). Because the
spectrum of cancers and the underlying pathways to can-
cer differ between transplant recipients and the general
population (109), it is unlikely that transplantation simply
accelerates age-related processes leading to cancer. It is
unclear whether immunosuppression regimens affect the
biology of a cancer, although some evidence suggests that
cancers behave more aggressively in immunosuppressed
patients. Immunosuppression could reduce the ability to
clear early cancer precursors (109).
Although data on quality of life following transplantation
are few, the quality-of-life benefit does not appear to dif-
fer between older and younger recipients (110,111). In
some cases, reported life satisfaction among recipients
older than 60 years is actually higher (112,113). Across
organs, the most important aspects of HRQOL differ be-
tween older and younger recipients (114,112,115). How-
ever, the effects of age on posttransplant HRQOL are com-
plex, whether in older patients receiving a transplant or in
patients aging after a transplant. One study suggests an
immediate drop, then rebound, in quality of life for donors
(116), but more data are needed.
Health Disparities in Transplantation
Across all ages, ESRD incidence of end-stage renal disease
is four times greater among racial and ethnic minorities
(117), but Hispanics are less likely to receive preemptive
transplants, and African Americans are less likely to be
waitlisted and transplanted in general (118,119). Compro-
mised health literacy (120), increased likelihood of higher
disease severity requiring emergency treatment (121), vari-
able or suboptimal discussions of transplantation and living
organ donations (122,123) and an apparent hesitation on
the part of minorities to donate organs (124–127) all con-
tribute to this disparity. Racial and ethnic disparities in ac-
cess to transplantation have improved somewhat with the
aid of home-based educational approaches (128), changes
in donor kidney allocation policy (129,130), amended Medi-
care coverage rules, the establishment of the National Liv-
ing Donor Assistance Center and changes in provider re-
imbursements for patient education.
Little is known about racial and ethnic differences in long-
term posttransplant outcomes (131). Across organs, graft
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and patient survival rates are highest for Asian and Hispanic
recipients and lowest for African American recipients, with
Non-Hispanic Whites in the middle. Among kidney recip-
ients, the benefits of preemptive transplantation are ob-
served predominantly among White recipients. Hepatitis
C infection, a risk factor for graft failure, is seen at higher
rates among African American recipients, and disparities
in outcomes are confounded by issues of access to trans-
plantation. However, adjustment for these factors does not
completely explain the worse outcomes in African Ameri-
cans. More work is needed to identify factors underlying
disparities in outcome, and no specific data address age
or functional status issues in minority versus nonminority
transplant recipients.
Health Care Utilization and Cost
The full cost implications of transplanting older recipients
or using organs from older donors are poorly defined. The
financial impact of elderly candidates includes the incre-
mental costs of additional evaluation, age-specific costs
incurred in the short term following transplant, and longer-
term costs that are related but more difficult to attribute
to the transplant procedure. The financial impact of older
donor organs includes costs related to discarded organs,
longer-term organ nonfunction and dysfunction and shorter
graft survival. Cost-effectiveness analyses often empha-
size quality-adjusted life years saved (QALYS), but it is
not clear whether the comparator in such analyses is the
younger donor or recipient or a therapeutic alternative to
transplantation. Moreover, cost variations between cen-
ters for otherwise comparable patient populations arise
from variations in practice, which are more likely to re-
flect institutional culture than patient needs. Selection bi-
ases against transplantation in older adults might reflect
providers’ risk aversion rather than empirical evidence,
which might become more important as regulators and
payers focus more on patient outcomes. Moreover, analy-
ses of cost- and comparative-effectiveness must also ad-
dress the moral and ethical appropriateness of therapeutic
decisions, especially as patient-centeredness and shared
decision making become more prevalent in health care
delivery.
Despite these difficulties in analyzing cost-effectiveness
data, a decision analysis of kidney transplantation in older
adults (113) suggests that the incremental cost of a QALYS
is sensitive to older age, length of time on the waitlist, and
potential for resource utilization associated with comorbidi-
ties and posttransplant complications. However, resource
utilization among older donors and recipients is difficult to
predict, and the few studies that have addressed it (132–
135) have produced conflicting results or failed to compare
predictors in older versus younger patients. As suggested
by data from other high-intensity care scenarios (136,137),
the inclusion of geriatric assessments (138) can prove use-
ful in decisions about transplantation in older adults, but
whether these assessments can predict resource utiliza-
tion among older recipients is not yet clear.
Future Research Directions
Although advanced age has been associated with com-
promised posttransplant outcomes, it is likely a proxy
for stronger predictors, such as functional status, phys-
iologic organ reserve, or comorbidity. There is a critical
need to address basic science issues of aging in trans-
plantation with the potential to shape clinical investiga-
tions and protocols, but rodent models of aging may not
closely mimic human aging (139). Further, few clinical
studies have directly explored transplantation in older pa-
tients, but further research in this population could guide
the education, selection and management of appropriate
candidates.
Critical areas of research need are comprehensively listed
in Table 1, but can be summarized into several broad
themes:
1. What critical immune mechanisms that change with
age and life-long viral infections (e.g. CMV, hepatitis
C) differentially affect transplant outcomes, and how
should these influence patient management?
2. Age serves as a surrogate for many other factors, such
as functional status, body composition, or comorbid-
ity. What is the contribution of each, and how can that
better guide selection of donors and recipients, organ
allocation systems and clinical management of trans-
plant recipients?
3. What is the impact of transplantation and chronic im-
mune suppression on the aging process in various or-
gan systems? Does that alter prevention and treatment
strategies?
4. How can functional outcomes, comorbidity, life-
expectancy and patient-centered results be better in-
corporated into transplant programs and quality met-
rics to assess ‘success’ in older patients?
Several datasets and cohorts are available to explore gen-
eral and organ-specific questions about the role of age in
issues of organ allocation, donor and recipient selection,
long-term outcomes and health disparities (Table 1). How-
ever, efforts to collect and test the role of novel risk predic-
tors in older adults, particularly those not in registries, are
critical, as existing registries lack the granularity required
to move this field forward. Future research will require
multidisciplinary collaborations, harmonization of existing
databases with primary data collection, and a uniform lan-
guage of variables to include in new studies. This research
will also need measures that are reliable, reproducible,
easy to use, and focused on end points valued by older
recipients. Some of these measures could aid in predicting
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Table 1: Questions and potential datasets or cohorts for future biomedical, health outcomes and public policy research
Area Question or cohort
Organ allocation 1. How do we balance age, functional status, expected years of life to be gained and alternative
therapies in a severity of illness-based allocation system?
2. Who are the right candidates to receive organs from older or other ‘marginal’ donors, how can we
educate those candidates, and how can we match ECD organs to the best recipients?
3. Should organ allocation algorithms for thoracic transplant attempt to age-match donors and
recipients?
4. Can we expand donor criteria further; how old is too old? How do we reduce the rate of organ
discard?
5. What strategies can be taken to increase the opportunity for heart transplant for older adults?
6. What safety issues should be considered for older living donors?
7. What is the impact of regulatory policies that emphasize very low rates of graft failure and mortality
on transplant centers’ willingness to transplant older recipients?
Reducing health disparities 1. What are the best methods for providers to communicate with minority patients and their families
about treatment options? Do these vary by age and/or life experiences?
2. What are the best ways to engage in shared decision making and educate minority patients about
treatment options?
3. What are the best ways to ensure compliance with established Medicare standards without
unintended adverse effects?
4. What biologic, behavioral and social mechanisms contribute to the racial and ethnic differences in
long-term posttransplant outcomes?
5. Can racial and ethnic disparities be separated from socioeconomic disparities?
Recipient selection 1. What are the age-specific barriers to becoming transplant eligible?
2. What are the age-related factors (e.g. functional status, cognitive impairment), for which age is
currently used as a surrogate marker, that affect long-term outcomes?
3. Since comorbidity and poor physiologic reserve is common even at younger ages in those with
end-stage organ failure, could younger recipients also benefit from a comprehensive ‘geriatric’
assessment to identify those at risk for adverse outcomes?
4. What is the rationale for colonoscopy, stress testing and mammography before transplantation in
older adults?
5. Do specific cognitive, health literacy and medication adherence tests predict transplant outcomes?
Can they be used to optimize candidate selection at all ages?
Recipient counseling 1. Are there age-related differences in risk acceptance for transplant? Are older adults less or more
interested in the risk trade-offs of the transplant?
2. Are age-specific interventions, for example counseling about higher posttransplant mortality or




1. How does aging impact innate and cellular (T and B cell) responses to organ transplantation?
2. Are immune senescence and exhaustion the same or different phenomena? How are they affected
by end-stage organ failure?
3. Do age-related immune defects arise from a loss of immune-activating responses, a gain of
inhibitory responses, or both? Should this influence selection of immune suppression strategy?
4. Are age-related immune changes primarily intrinsic (e.g. donor dominant), extrinsic (e.g. recipient
dominant), or both?
5. What are the roles of specific viruses, such as cytomegalovirus or Epstein Barr virus, or their
combinations in immune senescence or exhaustion?
6. How does aging alter the development of processes potentially accelerated by chronic viral
infection (e.g. chronic vasculopathy)?
7. Should immunosuppressive strategies and infection prophylaxis vary by age and/or be based on
measures of immune exhaustion or senescence? How do comorbidities alter this interplay?
8. What clinical or laboratory parameters could guide immunosuppressive strategies in older adults?
9. To what extent do immunosuppressive drug absorption, distribution, metabolism and excretion
change in the older adult?
10. Are older recipients at higher risk for immunosuppressant-related side effects?
11. How do drug pharmacodynamics change in older recipients?
12. What should the therapeutic level targets be in older patients?
13. What factors place older recipients at high risk for drug-related side effects, and what strategies
can be used to reduce toxicities?
14. What is the impact of treating acute rejection and using immune modulatory therapy in older
recipients?
15. Can novel measures of immune status that are more valuable in older patients be developed?
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16. How does immunosuppression influence the development or progression of coronary artery




1. How does aging impact ischemia/reperfusion injury?
2. What are the best practices for perioperative care (for example, tight glucose control) in older
transplant recipients?
3. What is the optimal approach to pain management in older transplant recipients?
4. Are exercise interventions beneficial and safe in older transplant recipients?
5. Does pretransplant exercise improve adherence to an exercise program after transplant?
6. What are the most effect methods to counsel transplant recipients with respect to exercise?
7. Should delirium prevention approaches differ between transplant recipients and other postoperative
patients?
8. Can transitional care and skilled nursing care needs be anticipated before a transplant?
Outcomes of
transplantation
1. What are acceptable short- and long-term outcomes for older adults?
2. Can comprehensive geriatric assessments predict outcomes, resource use and cost drivers in older
adults? Are these assessments superior to current expert opinion (the ‘eyeball test’)?
3. Are there biomarkers of acute kidney injury in the setting of kidney transplantation?
4. Are postrejection therapy recovery times for T cell numbers and function longer for older patients?
5. Is the increased risk for infection in older transplant recipients related to changes in immunity,
organ physiology, or other factors?
6. Are there correlations between immune function and other posttransplant outcomes?
7. How can risk for poorer long-term outcomes be assessed in patients with abnormal ejection
fractions or patients who have been revascularized because of coronary artery disease? Can
coronary angiograms be graded to assess this risk?
8. How can poor heart function in renal transplant patients be dissected from the effects of kidney
failure?
9. Does the increased incidence of cancer among older transplant recipients arise from elevated risk
or earlier onset?
10. What mechanisms contribute to the malignancies more common in transplant recipients?
11. At what ages is cancer screening in transplant recipients reasonable?
12. Are older transplant recipients more susceptible to declines in health-related quality of life
(HRQOL) with age? Are current instruments accurate for assessing pre- and posttransplant HRQOL
in older recipients?
13. What strategies are needed to optimize posttransplant HRQOL in older patients?
14. Will HRQOL benefits be sustained in less ‘ideal’ older transplant recipients?
Organ-specific research needs
Heart 1. Defined characteristics of an acceptable marginal heart, including studies of stored tissues to
identify characteristics of hearts that might have been used for transplantation
2. Improved risk models based on physiological age
3. Improved benchmarks for utility, attitudes and expectations
4. Improved use of mechanical device support as a bridge to transplant, as well as a definition of
conditions under which mechanical device support should be the final goal
Kidney 1. Better understanding of the relationships among physiologic decline, early allograft function and
long-term posttransplant outcomes
2. Comparative effectiveness studies of dialysis versus transplantation, specific to older adults and
informed by novel risk prediction metrics, such as functional status and frailty
3. Studies of early risk and long-term outcomes in older living donors
4. Continued study and discussion of the best allocation policies for older transplant candidates
5. Dissemination studies of evidence-based practices regarding expanded criteria donors
Lung 1. Studies to understand the referral bias for lung transplantation
2. Studies on the use of biomarkers to stratify older lung recipients according to risk
3. Studies on how medication management, bronchoscopic surveillance and monitoring for acute
rejection, and rehabilitation differ by age
4. Studies of palliative care in the management of organ transplant candidates and recipients
5. Better tools to predict, prevent and manage delirium and atrial fibrillation
Liver 1. Understanding of how hepatic carcinoma, an indication for liver transplant, affects risk for
posttransplantation malignancy and postcirrhotic outcomes
2. Understanding of how age affects the risk for morbidity and mortality of living donors
3. Studies on the value of adding geriatric assessments and related tools to risk models such as MELD
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4. A panel of objective clinical, biochemical, imaging, genomic, proteomic and other biomarkers to
define a risk index
5. Objective measures, including function, muscle mass, bone density and fat in liver and muscle to
understand the feasibility and efficacy of intervention studies to mitigate age-associated effects and
improve long-term outcomes
6. Improved donor–recipient matching to minimize waste
7. Assessments of tolerance, immune activation and immune surveillance in predicting outcomes
before and after transplantation
Datasets and Cohorts
Organ transplantation • SRTR (all organs)
• Transplant center-specific biorepositories (all organs)
• Intermacs, an LVAD registry (heart)
• International Society of Heart and Lung Transplantation (ISHLT) Registry (heart, lung)
• Clinical Trials in Organ Transplantation (CTOT, heart, kidney, liver)
• Lung Transplant Outcomes Group (lung)
• Genomics of Chronic Allograft Rejection (GoCAR, kidney)
• The Long-Term Deterioration of Kidney Allograft Function (DeKAF, kidney)
• The Long-Term Deterioration of Kidney Allograft Function Genomics (DeKAF Genomics, kidney)
• Adult to Adult Living Donor Liver Transplantation study (A2ALL, liver)
• NIDDK Liver Transplant Database (liver)
Geriatric • Medicare Advantage
• Nurses Health Study
• Physicians Health Study
• National Institute on Aging longitudinal cohorts (for example, Health and Retirement Study,
Baltimore Longitudinal Study on Aging, Multi-Ethnic Study of Atherosclerosis)
Genomics/biomarkers Genomics of Transplantation Cooperative Research Program
Quality of Life Database on Health-Related Quality of Life (Singer)
postoperative outcomes and in stratifying candidates
based on anticipated risk.
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